Belgium· BE-AMP-SAM433781-00
Ryzodeg 100 U/ml
A medicinal product containing insulin degludec, registered in Belgium by Novo Nordisk.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Insulin Degludec
- Manufacturer
- Novo Nordisk
- Country
- Belgium (BE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insulin degludec in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTRESIBANovo Nordisk A/S, Bagsvaerd
- United StatesInsulin DegludecNovo Nordisk Pharma, Inc.
- United KingdomTresiba FlexTouch 100units/ml solution for injection 3ml pre-filled pensNovo Nordisk Ltd
- FinlandTresibaOrifarm Oy
- SpainTRESIBA 100 UNIDADES/ML FLEXTOUCH SOLUCION INYECTABLE EN PLUMA PRECARGADANovo Nordisk A/S
- SwedenTresiba FlexPen 100 enheter/ml Injektionsvätska, lösning i förfylld injektionspennaNovo Nordisk A/S
- SwitzerlandTresiba FlexTouch 100 E/ml, InjektionslösungNovo Nordisk Pharma AG
- IcelandTresibaNovo Nordisk A/S*
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Tresiba Flexpen, Tresiba Flextouch
- Norway · Tresiba, Tresiba Flexpen
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7222f8ea-d6ec-4283-ad77-face643baf5f GET /v1/drugs/7222f8ea-d6ec-4283-ad77-face643baf5f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection in pre-filled pen",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Ryzodeg 100 U/ml",
"name_fr": "Ryzodeg 100 U/ml",
"name_nl": "Ryzodeg 100 U/ml",
"amp_code": "SAM433781-00",
"strengths": [
"70.0000",
"30.0000"
],
"pack_count": 0,
"substances": [
"Insulin Degludec",
"Insulin Aspart"
],
"medicine_type": "ALLOPATHIC",
"atc_description": null,
"authorisation_numbers": null
}See everything about insulin degludec.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.